Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

News · June 07, 2021

ASCO 2021: Nivolumab Plus Chemotherapy or Ipilimumab Offers Improved Outcomes Over Chemotherapy Alone in Advanced Esophageal Cancer

The dual immunotherapy regimen is the first chemotherapy-free first-line treatment to show benefit in this setting

PracticeUpdate Editorial Team


Further Reading